MAP3K5 and metabolic dysfunction-associated steatohepatitis: The apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib (GS-4997) has demonstrated reduced liver fibrosis, liver stiffness, and lobular inflammation in NASH patients and subjects with stage 2–3 fibrosis110.